Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irwin Lucki

Showing results (21-30 of 97) with videos related to

Pageof 10
Sort By:
European Journal of Pharmacology|February 1, 2005
The 5-HT1A receptor modulates the effects of cocaine on extracellular serotonin and dopamine levels in the nucleus accumbensChristine M Andrews, Hank F Kung, Irwin Lucki
European Journal of Pharmacology|February 23, 2002
Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim testJohn F Cryan, Michelle E Page, Irwin Lucki
Psychopharmacology|March 11, 2010
Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in ratsGregory V Carr, Lee E Schechter, Irwin Lucki
Psychopharmacology|October 13, 2005
Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension testJames J Crowley, Julie A Blendy, Irwin Lucki
Annual Review of Pharmacology and Toxicology|January 10, 2020
Kappa Opioid Receptor Antagonists as Potential Therapeutics for Stress-Related DisordersMoriah L Jacobson, Caroline A Browne, Irwin Lucki
Neuroscience and Biobehavioral Reviews|May 17, 2005
Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming testJohn F Cryan, Rita J Valentino, Irwin Lucki
Neurobiology of Stress|February 5, 2016
Corticosterone exposure augments sensitivity to the behavioral and neuroplastic effects of fluoxetine in C57BL/6 miceShivon A Robinson, Bethany R Brookshire, Irwin Lucki
Harvard Review of Psychiatry|January 9, 2020
Novel Targets to Treat Depression: Opioid-Based TherapeuticsCaroline A Browne, Moriah L Jacobson, Irwin Lucki
Neuropharmacology|October 5, 2022
(2R,6R)-hydroxynorketamine (HNK) reverses mechanical hypersensitivity in a model of localized inflammatory painJonathan G Yost, Caroline A Browne, Irwin Lucki
Advances in Drug and Alcohol Research|September 30, 2022
Buprenorphine as a Treatment for Major Depression and Opioid Use DisorderAmanda B Namchuk, Irwin Lucki, Caroline A Browne
Pageof 10

Showing results (21-30 of 97) with videos related to

Sort By:
Pageof 10
European Journal of Pharmacology|February 1, 2005
The 5-HT1A receptor modulates the effects of cocaine on extracellular serotonin and dopamine levels in the nucleus accumbensChristine M Andrews, Hank F Kung, Irwin Lucki
European Journal of Pharmacology|February 23, 2002
Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim testJohn F Cryan, Michelle E Page, Irwin Lucki
Psychopharmacology|March 11, 2010
Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in ratsGregory V Carr, Lee E Schechter, Irwin Lucki
Psychopharmacology|October 13, 2005
Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension testJames J Crowley, Julie A Blendy, Irwin Lucki
Annual Review of Pharmacology and Toxicology|January 10, 2020
Kappa Opioid Receptor Antagonists as Potential Therapeutics for Stress-Related DisordersMoriah L Jacobson, Caroline A Browne, Irwin Lucki
Neuroscience and Biobehavioral Reviews|May 17, 2005
Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming testJohn F Cryan, Rita J Valentino, Irwin Lucki
Neurobiology of Stress|February 5, 2016
Corticosterone exposure augments sensitivity to the behavioral and neuroplastic effects of fluoxetine in C57BL/6 miceShivon A Robinson, Bethany R Brookshire, Irwin Lucki
Harvard Review of Psychiatry|January 9, 2020
Novel Targets to Treat Depression: Opioid-Based TherapeuticsCaroline A Browne, Moriah L Jacobson, Irwin Lucki
Neuropharmacology|October 5, 2022
(2R,6R)-hydroxynorketamine (HNK) reverses mechanical hypersensitivity in a model of localized inflammatory painJonathan G Yost, Caroline A Browne, Irwin Lucki
Advances in Drug and Alcohol Research|September 30, 2022
Buprenorphine as a Treatment for Major Depression and Opioid Use DisorderAmanda B Namchuk, Irwin Lucki, Caroline A Browne
Pageof 10